• CCO
• HIV
• Live Events
• Managing Dyslipidemia

Join Drs. Glesby and Stein as they review evidence for managing HIV-infected patients with dyslipidemia-should one switch antiretroviral therapy or add lipid-lowering agents?

Registration for this activity is open to physicians and healthcare professionals actively involved in the delivery of care to HIV-infected patients. Other restrictions may apply.

• Agenda
• Faculty
• CME Information
• Accreditation

Program Overview

You are invited to attend a teleconference featuring expert faculty as they review the evidence supporting both sides of this important clinical debate.

• The case for switching antiretroviral therapy
• The case for adding lipid-lowering agents
• Case studies

Purpose

The purpose of this activity is to enable participants to assess the clinical impact of antiretroviral switch strategies and the use of lipid-lowering agents in HIV-infected patients with dyslipidemia.

Target Audience

This activity is intended for physicians, registered nurses, and other healthcare professionals involved in the management of HIV-infected patients.

Learning Objectives

• Summarize factors associated with dyslipidemia in HIV-infected patients
  
  
• Describe a step-by-step approach to developing a management plan for addressing dyslipidemia in an HIV-infected patient
  
  
• Recount clinical data on the impact of antiretroviral switch strategies on dyslipidemia
  
  
• Discuss considerations related to the use of lipid-lowering agents in HIV-infected patients, including issues related to safety, efficacy, and drug-drug interactions